Ortin Laboratories Limited
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti-diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-p… Read more
Ortin Laboratories Limited (ORTINLAB) - Total Liabilities
Latest total liabilities as of March 2024: ₹38.40 Million INR
Based on the latest financial reports, Ortin Laboratories Limited (ORTINLAB) has total liabilities worth ₹38.40 Million INR as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ortin Laboratories Limited - Total Liabilities Trend (2009–2024)
This chart illustrates how Ortin Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ortin Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Ortin Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pudjiadi Prestige Tbk
JK:PUDP
|
Indonesia | Rp19.21 Billion |
|
Circle Internet Group, Inc.
NYSE:CRCL
|
USA | $73.76 Billion |
|
Riedel Resources Ltd
AU:RIE
|
Australia | AU$1.01 Million |
|
Nova Net Lease REIT
PINK:NNLRF
|
USA | $3.40 Million |
|
AIS Resources Ltd
V:AIS
|
Canada | CA$2.33 Million |
|
Burzynski Research
PINK:BZYR
|
USA | $69.61K |
|
Sultan Resources Ltd
AU:SLZ
|
Australia | AU$389.52K |
|
Mace Security Intl
PINK:MACE
|
USA | $4.42 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Ortin Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ortin Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ortin Laboratories Limited (2009–2024)
The table below shows the annual total liabilities of Ortin Laboratories Limited from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-03-31 | ₹38.40 Million | -62.83% |
| 2023-03-31 | ₹103.32 Million | +5.99% |
| 2022-03-31 | ₹97.48 Million | -1.64% |
| 2021-03-31 | ₹99.10 Million | -89.31% |
| 2020-03-31 | ₹927.02 Million | +15.89% |
| 2019-03-31 | ₹799.92 Million | +61.32% |
| 2018-03-31 | ₹495.85 Million | +31.37% |
| 2017-03-31 | ₹377.44 Million | -10.27% |
| 2016-03-31 | ₹420.64 Million | -6.17% |
| 2015-03-31 | ₹448.29 Million | -11.41% |
| 2014-03-31 | ₹506.05 Million | -4.00% |
| 2013-03-31 | ₹527.16 Million | -16.16% |
| 2012-03-31 | ₹628.75 Million | +81.32% |
| 2011-03-31 | ₹346.77 Million | +357.61% |
| 2010-03-31 | ₹75.78 Million | -9.09% |
| 2009-03-31 | ₹83.36 Million | -- |